$4,750.00
This Meddevicetracker analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the market for bone densitometers (including DXA, QUS, QCT, RA, and SXA systems) and bone turnover marker tests for the US, the five major EU markets, Japan, and the rest of world markets.
The prevalence of osteoporosis is a major driver of the market for bone densitometers and bone turnover marker tests; the disease affects more than 200 million people worldwide.
The combined global market for bone densitometers and bone turnover marker tests totaled approximately $328m in 2018, and is expected to climb at a rate of 2.6% over the forecast period covered by this analysis.
Within the combined market, bone densitometers accounted for approximately 72% of total sales.
Leading competitors in the market for bone densitometers include General Electric and Hologic. In the market for bone turnover marker tests, leading competitors include Roche and Alere.
This medical market and technology report provides a comprehensive discussion of the global market for bone densitometers and bone turnover marker tests. Geographic markets covered by this analysis comprise the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
This report provides the following useful information:
Executive Summary…………………………………………………………………………………………………………….ES-1
i. Market analysis…………………………………………………………………………………………………………ES-1
a. Selected market drivers and limiters…………………………………………………………ES-5
b. Market leaders……………………………………………………………………………………….ES-5
ii. Methodology …………………………………………………………………………………………………………..ES-5
Exhibit ES-1: Bone densitometry systems and bone turnover marker tests, combined market forecast, by segment ($m), 2017-23………………………………………..ES-2
Exhibit ES-2: Bone densitometry systems and bone turnover marker tests, combined market forecast, by region ($m), 2017-23……………………………………………ES-4
1. Overview of Osteoporosis………………………………………………………………………………………………… 1-1
1.1 Prevalence …………………………………………………………………………………………………………….. 1-1
1.2 Fracture incidence and economic costs…………………………………………………………………….. 1-2
1.3 Types of osteoporosis……………………………………………………………………………………………… 1-5
1.4 Risk factors…………………………………………………………………………………………………………….. 1-6
1.5 Treatment……………………………………………………………………………………………………………… 1-9
1.6 Bibliography…………………………………………………………………………………………………………. 1-11
Exhibit 1-1: Osteoporosis prevalence rate, per 10,000 population, US ……………………………………. 1-1
Exhibit 1-2: Osteoporosis prevalence, five major EU markets ………………………………………………… 1-2
Exhibit 1-3: Osteoporosis prevalence, Japan………………………………………………………………………… 1-2
Exhibit 1-4: Osteoporosis-caused fracture incidence in the EU, by fracture site ……………………….. 1-3
Exhibit 1-5: Number of visits for osteoporotic fractures (in 000s), US……………………………………… 1-4
Exhibit 1-6: Types of osteoporosis and their primary causes and fracture types ………………………. 1-5
Exhibit 1-7: Leading risk factors for osteoporosis………………………………………………………………….. 1-6
Exhibit 1-8: Population growth of 65+ years age group, selected countries, 2000-50………………… 1-7
2. Bone Densitometry Products Market ……………………………………………………………………………….. 2-1
2.1 Bone densitometry overview …………………………………………………………………………………… 2-1
2.1.1 Dual-energy X-ray absorptiometry……………………………………………….. 2-3
2.1.2 Single-energy X-ray absorptiometry …………………………………………….. 2-4
2.1.3 Radiographic absorptiometry………………………………………………………. 2-4
2.1.4 Quantitative computed tomography ……………………………………………. 2-4
2.1.5 Quantitative ultrasound……………………………………………………………… 2-4
2.1.6 Software-based densitometry systems…………………………………………. 2-5
2.1.7 Hospital-based densitometry systems………………………………………….. 2-6
2.1.8 Office-based densitometry systems……………………………………………… 2-6
2.2 Densitometry products……………………………………………………………………………………………. 2-6
2.2.1 BeamMed…………………………………………………………………………………. 2-7
2.2.2 CompuMed……………………………………………………………………………….. 2-7
2.2.3 Furuno Electric Company ……………………………………………………………. 2-8
2.2.4 GE Healthcare/General Electric Company …………………………………….. 2-8
2.2.5 Hologic……………………………………………………………………………………… 2-8
2.2.6 Swissray……………………………………………………………………………………. 2-8
2.2.7 Emerging company…………………………………………………………………… 2-12
2.3 Market analysis…………………………………………………………………………………………………….. 2-12
2.3.1 Market forecast: US………………………………………………………………….. 2-15
2.3.2 Market forecast: EU …………………………………………………………………. 2-18
2.3.3 Market forecast: Japan……………………………………………………………… 2-19
2.3.4 Market forecast: rest of the world……………………………………………… 2-20
2.3.5 Competitive analysis: global………………………………………………………. 2-21
2.4 Primary research…………………………………………………………………………………………………… 2-26
2.5 Bibliography…………………………………………………………………………………………………………. 2-29
Exhibit 2-1: Comparison of biochemical markers and bone densitometry for diagnosing and monitoring osteoporosis…………………………………………………………………………….. 2-2
Exhibit 2-2: Imaging modalities used to diagnose osteoporosis ……………………………………………… 2-5
Exhibit 2-3: Selected bone densitometry systems…………………………………………………………………. 2-9
Exhibit 2-4: DXA price range, US……………………………………………………………………………………….. 2-11
Exhibit 2-5: The Lunar iDXA dual-energy X-ray absorptiometry system………………………………….. 2-11
Exhibit 2-6: The Horizon dual-energy X-ray absorptiometry system………………………………………. 2-12
Exhibit 2-7: Bone densitometry systems market forecast, by region, 2017-23 ……………………….. 2-14
Exhibit 2-8: Bone densitometry systems global market, share by supplier, 2017…………………….. 2-21
Exhibit 2-9: Bone densitometry systems US market, share by supplier, 2017…………………………. 2-23
Exhibit 2-10: Bone densitometry systems five major EU markets, share by supplier, 2017 ………… 2-24
Exhibit 2-11: Bone densitometry systems Japan market, share by supplier, 2017 …………………….. 2-25
Exhibit 2-12: Bone densitometry systems RoW market, share by supplier, 2017………………………. 2-26
Exhibit 2-13: Meddevicetracker survey: percentage of bone density scans performed to screen for osteoporosis, 2018……………………………………………………………………… 2-26
Exhibit 2-14: Meddevicetracker survey: How did the number of bone density scans you performed or referred in 2018 compare to 2017?……………………………………………… 2-27
Exhibit 2-15: Meddevicetracker survey: type of bone densitometry system used, as a percentage of total bone scans…………………………………………………………………. 2-28
3. Market for Bone Turnover Marker Tests……………………………………………………………………………. 3-1
3.1 Biochemical markers overview…………………………………………………………………………………. 3-1
3.1.1 Types of bone turnover markers………………………………………………….. 3-2
3.1.2 Applications………………………………………………………………………………. 3-5
3.1.3 Limitations………………………………………………………………………………… 3-5
3.2 Bone turnover marker testing products…………………………………………………………………….. 3-6
3.2.1 Alere/Abbott …………………………………………………………………………….. 3-6
3.2.2 Beckman Coulter/Danaher………………………………………………………….. 3-6
3.2.3 Immunodiagnostic Systems ………………………………………………………… 3-6
3.2.4 Orion Diagnostica/Orion Group …………………………………………………… 3-7
3.2.5 Quest Diagnostics………………………………………………………………………. 3-7
3.2.6 Quidel ………………………………………………………………………………………. 3-7
3.2.7 Roche Diagnostics/F. Hoffmann-La Roche …………………………………….. 3-7
3.3 Reimbursement……………………………………………………………………………………………………… 3-9
3.4 Market analysis………………………………………………………………………………………………………. 3-9
3.5 Competitive analysis……………………………………………………………………………………………… 3-12
3.6 Primary research…………………………………………………………………………………………………… 3-12
3.7 Bibliography…………………………………………………………………………………………………………. 3-14
Exhibit 3-1: The bone remodeling cycle……………………………………………………………………………….. 3-2
Exhibit 3-2: Comparison of the types of bone turnover marker tests………………………………………. 3-3
Exhibit 3-3: Selected bone turnover marker tests…………………………………………………………………. 3-8
Exhibit 3-4: Bone turnover marker tests market forecast, by region, 2017-23………………………… 3-11
Exhibit 3-5: Bone turnover marker tests global market, share by supplier, 2017…………………….. 3-12
Exhibit 3-6: Meddevicetracker survey: How effective do you consider bone turnover marker tests for identifying patients at high risk of osteoporosis? ………………………………….. 3-13
Exhibit 3-7: Meddevicetracker survey: How effective do you consider bone turnover marker tests for monitoring treatment for osteoporosis? ……………………………………………… 3-13
APPENDIX: COMPANY LISTING……………………………………………………………………………………………………..A-1
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!